(2019) showed an increasing trend of erythromycin resistant GBS isolates recovered from neonatal disease in the US between 2006 (34.7%) and 2015 (49.1%), which may be a consequence of the wide implementation of IAP in the country.
← all excerpts
The landscape of antimicrobial resistance in the neonatal and multi-host pathogen group B <i>Streptococcus:</i> review from a One Health perspective.
1
—
—